Insulin Glargine

@article{McKeage2012InsulinG,
  title={Insulin Glargine},
  author={Kate McKeage and Karen L. Goa},
  journal={Drugs},
  year={2012},
  volume={61},
  pages={1599-1624}
}
SummaryAbstractInsulin glargine is a recombinant human insulin analogue produced by DNA technology using a nonpathogenic strain of Escherichia coli. Two modifications of human insulin result in a stable molecule which is soluble in slightly acidic conditions (pH 4.0) and precipitates in the neutral pH of subcutaneous tissue. Because of these properties, absorption of insulin glargine is delayed and the analogue provides a fairly constant, basal insulin supply without peaks in plasma insulin… Expand
Insulin Glargine
TLDR
In conclusion, insulin glargine is an effective and well tolerated basal insulin therapy when given as a single daily subcutaneous injection to patients with diabetes, with benefits in terms of glycaemic control and reduced frequency of hypoglycaemia over regimens based on conventional basal insulins. Expand
Long-acting hypoglycemic effects of PEGylated FGF21 and insulin glargine in mice with type 1 diabetes.
  • P. Xu, X. Ye, +5 authors D. Li
  • Medicine
  • Journal of diabetes and its complications
  • 2015
TLDR
PEG-FGF21 achieves glucose clearance by accelerating glycolysis by up-regulating expression of GK and GLUT1 and inhibiting gluconeogenesis via down-regulation of G6Pase and PEPCK expression through qRT-PCR. Expand
Basalog® is similar to Lantus® in producing glycemic control in patients with type 1 diabetes mellitus on multiple daily insulin regimens
TLDR
Basalog® was found to have similar efficacy and safety as Lantus® in treatment of patients with type 1 diabetes mellitus and there was no statistically significant difference between the groups with respect to change in HbA1c. Expand
New approaches to the use of insulin in patients with diabetic ketoacidosis.
TLDR
It has been demonstrated that the use of subcutaneous rapid-acting insulin analogs represents a safe, cost-effective and technically simpler treatment that precludes intensive care unit admission without significant differences in outcome in the management of patients with mild to moderate, uncomplicated DKA. Expand
Transgenic Expression and Identification of Recombinant Human Proinsulin in Peanut
The increased incidence of diabetes, coupled with the introduction of alternative insulin delivery methods that rely on higher doses, is expected to result in a substantial escalation in the futureExpand
Insulin-induced vascular redox dysregulation in human atherosclerosis is ameliorated by dipeptidyl peptidase 4 inhibition
TLDR
Results uncover how DPP4 inhibition induces insulin sensitization in the vascular wall and suggest that cotreatment with insulin may be therapeutic for patients with cardiometabolic disease and reveal the detrimental effects of insulin on vascular redox state and endothelial function. Expand
Willingness to pay for inhaled insulin
TLDR
Diabetic patients, particularly those who are not using insulin, indicated that they would prefer inhaled insulin over insulin injection and would be willing to pay a substantial amount per month to use it, and multiple regression analysis showed that income was significantly associated with WTP for inhale insulin. Expand
Insulin Therapy: The Old, the New and the Novel-An Overview.
TLDR
Insulin therapies that are currently available for use in the management of diabetes, from the old to the new and novel, and briefly discuss insulin use in special populations are discussed. Expand
Human insulin gene expressing with Bombyx mori multiple nucleopolyhedrovirus (BmMNPV) expression system
TLDR
Using human genomic DNA as a template, the human insulin gene was cloned and used to construct various reBmMNPVbacmids and the highest expression was shown with the CPPD- BmM NPV bacmid, which was about two times that of the wild type of reBMMNPVsbacmid. Expand
Production of proinsulin in marker-free transgenic tobacco plants using CRE/loxP system
TLDR
A selective marker-free system without crossing to produce PROINSULIN in transgenic plant using the CRE/loxP system and this auto-excision strategy provides efficient means of removing the selectable marker gene from transgenic plants. Expand
...
1
2
...

References

SHOWING 1-10 OF 66 REFERENCES
Insulin Glargine
TLDR
Four large clinical trials of up to 28 weeks’ duration have shown that a single bedtime dose of insulin glargine, in combination with preprandial short-acting insulin, is as effective or more effective than once or twice daily NPH plus short- acting insulin in improving glycaemic control in patients with type 1 diabetes mellitus. Expand
Insulin glargine: the first clinically useful extended-acting insulin in half a century?
  • P. Home
  • Medicine
  • Expert opinion on investigational drugs
  • 1999
TLDR
It appears that insulin glargine is a genuinely new addition to the insulin family, and with further clinical experience it may well be possible to achieve better basal blood glucose control (without enhanced risk of hypoglycaemia), particularly at night or in conjunction with rapid-acting insulin analogues. Expand
Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
TLDR
Basal insulin glargine administered once daily for 4 weeks as part of a basal-bolus multiple daily insulin regimen was safe and more effective in lowering fasting plasma glucose levels than NPH in patients with type 1 diabetes. Expand
Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.
TLDR
Lower FPG levels with fewer episodes of hypoglycemia were achieved with insulin glargine compared with once- or twice-daily NPH insulin as part of a basal-bolus regimen in patients with type 1 diabetes. Expand
A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.
TLDR
Basal insulin therapy with insulin glargine once a day appears to be as safe and at least as effective as using NPH insulin once or twice a day in maintaining glycemic control in patients with type 1 diabetes receiving basal-bolus insulin treatment with insulin lispro. Expand
Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. RhIGF-I in IDDM Study Group.
TLDR
It is demonstrated that rhIGF/insulin cotherapy improves glycemic control in patients with type 1 diabetes better than optimized insulin management alone; longer-term trials would be required to determine an acceptable benefit-risk profile. Expand
Treatment with human analog (GlyA21, ArgB31, ArgB32) insulin glargine (HOE901) resolves a generalized allergy to human insulin in type 1 diabetes.
TLDR
The case of a 45-year-old type 1 diabetic Japanese man with generalized allergy to human insulin, who was successfully treated with human analogs and insulin glargine (HOE901), and who was diagnosed with type 1 diabetes because of the high titer of anti-GAD antibody. Expand
Insulin analogs with improved pharmacokinetic profiles.
  • Brange, Vølund
  • Biology, Medicine
  • Advanced drug delivery reviews
  • 1999
TLDR
The present paper provides a historical review of the efforts to change the physicochemical and pharmacological properties of insulin in order to improve insulin therapy and shows that new strategies for optimal basal-bolus treatment are required for utilization of the new fast-acting analogs. Expand
Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
TLDR
Glargine is a peakless insulin, it lasts nearly 24 h, it has lower intersubject variability than NPH and ultralente, and it closely mimics CSII, the gold standard of basal insulin replacement. Expand
Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.
TLDR
Subcutaneous absorption of insulin glargine is delayed compared with NPH insulin and there is little or no difference in the absorption rate of insulinglargine between the main subcutaneous injection sites. Expand
...
1
2
3
4
5
...